研究单位：[1]Jiangsu Gensciences lnc.[2]Beijing Children's Hospital,Capital Medical University Beijing,Beijing,China,100045[3]Shenzhen Children's Hospita Shenzhen,Guangdong,China,518000[4]Nanfang Hospital of Southern Medical University Guangzhou,Guangzhou,China,510515[5]Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology Wuhan,Hubei,China,430000[6]The Affiliated Hospital of Qingdao University Qingdao,Shandong,China,266000[7]Chengdu Women's and Children's Central Hospital Chengdu,Sichuan,China,610000
研究目的：
Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection (FRSW107) Secondary objectives: To assess Safety and Tolerability by monitoring FVIII recovery and adverse events in Severe Hemophilia A.
